There is no clinical evidence from human studies that BPC-157 at therapeutic doses causes kidney damage
demonstrated that retrovirus-mediated Zfp488 over-expression could significantly promote an oligodendrogenic fate of differentiating SVZ neuronal stem cells and enhance functional recovery of cuprizone-treated mice (Soundarapandian et al., 2011)
Most forms require refrigeration after reconstitution and use within limited timeframes
CAS Numbers: 137525-51-0 (BPC-157)
Ongoing low-dose maintenance (experimental) Continuous dosing approach: Dose: 1-2mg daily OR 3-5mg 2-3x weekly Duration: Ongoing (not cycled) Goal: Maintain constant telomerase activation Status: Experimental, not from research protocols Rationale: Telomerase needs continuous activation to maintain telomere length Cyclic dosing may allow regression between cycles Low-dose continuous might provide stable benefits Similar to maintenance protocols for other peptides Continuous dosing options: Advantages of continuous: No "off" periods where benefits regress Potentially stronger cumulative anti-aging More like natural physiologic regulation Easier to stack with other peptides Disadvantages: Much higher annual cost ($1,800-3,600 vs $300-600) No long-term safety data Uncertain if better than cyclic approach Storage challenges (more reconstitution) Deviates from proven protocols Current recommendation: Stick with proven 10-day cycles for most users Consider continuous only if cyclic approach inadequate Start with standard protocol first Assess your individual response Consult with peptide-knowledgeable physician Use our peptide cycle planning guide to design your Epithalon protocol
On the other hand, 35 microRNAs were identified in oocytes at the MII stage, including miR-144, miR-1603, miR-190b, miR-29b, miR-29c, miR-29e, miR-412, and miR-449b
